ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
| - Industry | - Sector | Nikhil Lalwani CEO | XFRA Exchange | US00182C1036 ISIN |
| US Country | 897 Employees | - Last Dividend | 4 Jun 2012 Last Split | 5 May 2000 IPO Date |
ANI Pharmaceuticals, Inc. is a leading biopharmaceutical company that specializes in the development, manufacturing, and marketing of both branded and generic prescription pharmaceuticals, primarily in the United States and Canada. With its incorporation in 2001, the company has established a significant presence in the pharmaceutical industry, headquartered in Baudette, Minnesota. It serves a wide range of customers including retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals, underpinning its comprehensive approach to healthcare solutions.
ANI Pharmaceuticals excels in manufacturing a variety of oral solid dose products, such as tablets and capsules. These are designed for ease of use and effectiveness in treatment, catering to a wide range of therapeutic areas.
- Semi-solids, liquids, and topicalsThe company also produces semi-solid formulations, liquid medicines, and topical treatments. These products offer alternatives for patients requiring different delivery methods for their medications beyond traditional oral forms.
- Controlled substancesSpecializing in the highly regulated sector of controlled substances, ANI Pharmaceuticals demonstrates its commitment to maintaining stringent quality control and regulatory compliance, ensuring safe and reliable medications for conditions that require tightly controlled ingredients.
- Potent productsANI Pharmaceuticals has the capability to manufacture potent products that require special handling and manufacturing processes due to their high potency. These products are critical for treating more severe conditions, necessitating a higher level of expertise in their production.
- Contract development and manufacturing of pharmaceutical productsAside from its own product offerings, ANI Pharmaceuticals provides contract development and manufacturing services. This allows other companies to leverage ANI's expertise and facilities for the development and manufacturing of their pharmaceutical products, highlighting ANI's flexibility and capability in supporting the broader pharmaceutical industry.